Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Founded by Mexican billionaire and former Lazard banker Pablo Legorreta, the firm buys royalties on potential blockbuster drugs from academic labs and biotechnology companies, which in turn use the ...

Cytokinetics has suggested aficamten has a competitive clinical profile to BMS' drug – pointing to strong data on exercise capacity, symptoms, biomarkers, cardiac structure and function ...

The pipeline had included China rights to aficamten, a Cytokinetics drug in development for symptomatic obstructive hypertrophic cardiomyopathy. Last week, Corxel sold its aficamten development ...

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to invest in the healthcare firm, and shifting to an internal management could enhance ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of ...